Communicators

Salugen AG (FRA: SQZ.F) successfully conducts initial public offering of stock

Salugen stock rises over 70 percent in its first month as the first publicly-traded nutrigenomics company by listing on the FWB® Frankfurter Wertpapierbörse (the Frankfurt Stock Exchange)

ZURICH, SWITZERLAND and SAN DIEGO, CA USA – April 13, 2009 – Salugen® AG (www.salugen.com), a life sciences company, announces today the initial public offering of its stock traded on the FWB® Frankfurter Wertpapierbörse (the Frankfurt Stock Exchange) under the symbol SQZ (FRA:SQZ.F). In its first month, Salugen’s share price has increased over 70 percent despite uncertain economic times affecting the overall equity markets.

The Company is raising capital to invest in growing its commercial infrastructure in Europe and the USA, as well as exploring further growth through acquisitions. The banking institutions involved in the transaction include investment bank Sherbrooke Equity AG and security services from Societe Generale of Zurich, Switzerland.

Salugen began in early 2005 as a pioneer in nutritional genetics. In a few short years, the Company emerged from its “pilot stage” positioned to capture significant market share. Besides winning numerous awards for its research by the Natural Products Association – the largest natural products association in North America, some of the accomplishments of the first three years include:

• Conducting a dozen commercial pilots in Europe and the USA to evaluate the viability of nutrigenomics for joint health, obesity, alcoholism, illegal drug abuse, narcotic abuse, skin health, stress and other conditions;
• In-licensing multiple issued and pending intellectual property protections in Europe and the USA, as well as registering important trademarks;
• Completing multiple clinical studies and having over 15 publications in peer-reviewed scientific and medical journals;
• Going from start-up to about $1M in sales in its first year of commercial piloting demonstrating explosive growth potential; and,
• Accomplishing these feats on less than 1/10th of the funding of other companies in nutritional genetics.

To prepare Salugen for this milestone, the Company has participated in various programs to support its growth including being a member of the Morrison & Foerster Venture Network (www.mofo.com), a graduate of the San Diego CONNECT Springboard Program (www.connect.org), and a presenter at the Nutritional Capital Network (www.nutritioncapital.com).

About Salugen AG

Salugen™ is a life sciences company offering nutritional ingredients and gene testing to help reduce excessive cravings involved in smoking, weight problems, and alcohol and drug abuse. Salugen has a patent-protected, clinically proven nutritional formulation to reduce stress and cravings, as well as patent-protected gene tests to help identify these persons and customize their treatment. Simply, Salugen’s goal is to reduce or eliminate the illness, costs, and deaths associated with these preventable disorders. For additional information about the company, please visit http://www.salugen.com.

Investor Relations Information Contact:

Allegios Consulting GmbH.
Dusseldorfer Strasse 89
Meerbush
Web www.allegios-consulting.de
Email info@allegios-consulting.de
Telephone +4921327588734

Company Information Contact: Salugen AG, 877-258-4360, info@salugen.com, http://www.salugen.com

Forward Looking Statements

Certain statements in this press release are forward-looking. These forward-looking statements include references to the use of our laboratory tests and nutritional products. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use the testing or products correctly; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on physicians selling our products for a majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services; whether actions by the FDA, FTC or any other state regulatory body will restrict our ability to commercialize our products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; and whether we will be able to raise sufficient capital in the future, if required. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.



NEWSLETTER REGISTRIERUNG:
Aktuelle Pressemeldungen dieses Unternehmens direkt in Ihr Postfach:
http://www.irw-press.com/alert_subscription.php?lang=en&isin=CH0027529517

Mitteilung übermittelt durch IRW-Press.com. Für den Inhalt ist der Aussender
verantwortlich.
Kostenloser Abdruck mit Quellenangabe erlaubt.